Last Updated : January 29, 2025
Details
FilesGeneric Name:
pembrolizumab
Project Status:
Complete
Therapeutic Area:
Colorectal cancer
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0235-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Call for patient/clinician input open | November 02, 2020 |
---|---|
Call for patient/clinician input closed | December 24, 2020 |
Clarification: - Patient input submission received from Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network | |
Submission received | November 30, 2020 |
Submission accepted | December 14, 2020 |
Review initiated | December 15, 2020 |
Draft CADTH review report(s) provided to sponsor for comment | March 08, 2021 |
Deadline for sponsors comments | March 17, 2021 |
CADTH responses on draft review report(s) provided to sponsor | May 03, 2021 |
Expert committee meeting (initial) | May 14, 2021 |
Draft recommendation issued to sponsor | May 31, 2021 |
Draft recommendation posted for stakeholder feedback | June 10, 2021 |
End of feedback period | June 24, 2021 |
Final recommendation issued to sponsor and drug plans | July 09, 2021 |
Final recommendation posted | July 27, 2021 |
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | July 23, 2021 |
CADTH review report(s) posted | September 22, 2021 |
Files
Last Updated : January 29, 2025